. Author manuscript; available in PMC: 2023 Jan 1.

Published in final edited form as: J Allergy Clin Immunol. 2021 Jun 17;149(1):315–326.e9. doi: 10.1016/j.jaci.2021.06.008

TABLE I.

Clinical and laboratory characteristics of subjects with CVID

Characteristic	CVIDc	CVID	P value^*

No. of subjects	26	31
Sex: female (%)	15 (58)	18 (58)	>.999
Median age (y) (95% CI)	45.5 (39–52)	48 (38–54)	.636
Subjects (%) with history of:
Sinusitis	14 (54)	24 (77)	.091
Pneumonia	14 (54)	19 (61)	.601
Bronchiectasis	6 (23)	4 (13)	.486
Median lab value (95% CI)
Diagnostic IgG (mg/dL)	226 (100–345)	233 (89–366)	.922
Diagnostic IgA (mg/dL)	7 (0–13)	25 (7–49)	.045
Diagnostic IgM (mg/dL)	13.5 (0–40)	20.5 (6–33)	.595
Neutrophils (10³/μL)	3.1 (2.6–4.4)	3.3 (2.8–4.1)	.846
Lymphocytes (10³/μL)	1.0 (0.8–1.2)	1.5 (1.2–1.8)	.004
CD4⁺ T cells (/μL)	472 (333–781)	679 (504–857)	.058
CD8⁺ T cells (/μL)	224 (138–291)	428 (321–627)	.0004
CD16⁺CD56⁺ (/μL)	69.5 (48–135)	109 (78–222)	.127
CD19⁺ B cells (/μL)	65 (25–139)	190 (138–328)	<.0001

Categorical values were compared using Fisher exact test. Continuous values were compared using Kruskal-Wallis test. Values below the level of detection of the laboratory assay were recorded as 0. Significant P values are in boldface.